

ASX RELEASE

31 May 2024

Appendix 3Y – Change of Director's Interest Notices

In accordance with ASX Listing Rule 3.19A.2, Acusensus Limited (ASX: ACE) (Acusensus or the Company) attaches two Appendix 3Y – Change of Director's Interest Notices (Notices), which relate to securities granted to Alexander Jannink and Michael Giuffrida following shareholder approval at the last Annual General Meeting of Acusensus.

The Company notes that the directors' interests are the subject of the relevant Appendix 3G that was disclosed to the market at the time of issue. The Notices are being lodged outside of the time required by Listing Rule 3.19A due to an administrative oversight. In this instance, the Company initiated the changes of interest via the issue of options and performance rights and it was for the Company to notify the relevant directors of the change to their interests. The Company has reviewed its procedures around the issue of securities and notification procedures to ensure compliance with Listing Rules 3.19A and 3.19B in the future.

END

Enquiries

Anita Chow Chief Financial Officer, Acusensus Limited +61 408 261 554

Email: investor-relations@acusensus.com

Simon Hinsley Investor and Media Relations +61 401 809 653

Email: simon@nwrcommunications.com.au

This announcement is authorised by the Company Secretary of Acusensus Limited.

ASX RELEASE



About Acusensus

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus' first priority.

Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices also in Sydney, Brisbane, London (UK) and Las Vegas (United States).

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Acusensus Limited
ABN 17 625 2	231 941

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alexander Jannink
Date of last notice	4 August 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	Alexander Jannink is a director, shareholder
(including registered holder)	and beneficiary of Jannink & Associates Pty
Note: Provide details of the circumstances giving rise to the relevant interest.	Ltd ACN 622 744 870 as trustee for Jannink
interest.	Family Trust
Date of change	17 November 2023

01/01/2011 Appendix 3Y Page 1

⁺ See chapter 19 for defined terms.

No. of securities held prior to change	 16,750,000 fully paid ordinary shares, of which 8,375,000 fully paid ordinary shares are subject to voluntary escrow until the release of FY24 results. 510,660 unquoted options: 210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027; 220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and 80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031,
Class	of which 255,330 unquoted options are subject to voluntary escrow until the release of the FY24 results. Ordinary shares, unquoted options and
Number acquired	unquoted performance rights. 281,573 unquoted performance rights.
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	 1. 16,750,000 fully paid ordinary shares, of which 8,375,000 fully paid ordinary shares are subject to voluntary escrow until the release of FY24 results. 2. 510,660 unquoted options: a. 210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027; b. 220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and c. 80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031,

⁺ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of securities under employee incentive scheme and approved at the Company's 2023 Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)	
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?	
If prior written clearance was provided, on what date was	N/A
this provided?	

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name	e of entity Acusensus Limited
ABN	17 625 231 941

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Lawrence Giuffrida
Date of last notice	9 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	17 November 2023
No. of securities held prior to change	Nil
Class	Unquoted options
Number acquired	250,000
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	250,000 unquoted options exercisable at A\$1.00 and expiring on 17 November 2028.

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of securities under employee incentive scheme and approved at the Company's 2023 Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?	
If prior written clearance was provided, on what date was	N/A
this provided?	

Appendix 3Y Page 2 01/01/2011

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.